A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal Cancer
NCT07915921, Phase 1, Phase 2, Not yet recruiting, Genfleet Therapeutics (Shanghai) Inc.
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal Cancer | ClinicalTrials.gov |
| NCT number | NCT07915921 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Phase 1, Phase 2 | ClinicalTrials.gov |
| Enrollment | 150 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Genfleet Therapeutics (Shanghai) Inc. | ClinicalTrials.gov |
| Conditions | CRC | ClinicalTrials.gov |
| Interventions | Irinotecan, Oxaliplatin, GFH276, Fluorouracil (5-FU), Leucovorin, Bevacizumab, Cetuximab (CRC) | ClinicalTrials.gov |
| First posted | 2026-11-04 | ClinicalTrials.gov |
| Last updated | 2026-11-06 | ClinicalTrials.gov |
Registered outcomes 11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Phase Ib: Incidence and severity of AEs and SAEs | up to 24 months | Incidence and severity of AEs and SAEs | ClinicalTrials.gov |
| Primary | Phase Ib: The incidence of DLT events: The incidence of DLT events | First 28 days | The incidence of DLT events | ClinicalTrials.gov |
| Primary | Phase II: Objective response rate （ORR） | From first use of medication to disease progression，up to 24 months | Overall Response Rate assessed by investigators according to RECIST 1.1 | ClinicalTrials.gov |
| Secondary | ORR: | From first use of medication to disease progression，up to 24 months | Overall Response Rate assessed by investigators according to RECIST 1.1 | ClinicalTrials.gov |
| Secondary | OS | From first use of medication to disease progression，up to 24 months | Overall Survival | ClinicalTrials.gov |
| Secondary | Cmax | From first use of medication to C6，up to 6 months | Maximum plasma concentration | ClinicalTrials.gov |
| Secondary | DOR | From first use of medication to disease progression，up to 24 months | Duration of Response assessed by investigators | ClinicalTrials.gov |
| Secondary | DCR | From first use of medication to disease progression，up to 24 months | Disease Control Rate | ClinicalTrials.gov |
| Secondary | TTR | From first use of medication to disease progression，up to 24 months | Time To Response assessed by investigators | ClinicalTrials.gov |
| Secondary | PFS | From first use of medication to disease progression，up to 24 months | Progression-Free Survival assessed by investigators according to RECIST 1.1 | ClinicalTrials.gov |
| Secondary | Tmax | From first use of medication to C6，up to 6 months | Time to Maximum Concentration | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)